Video

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

Author(s):

Van K. Morris, MD

In Partnership With:

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Van K. Morris, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of immunotherapy in metastatic colorectal cancer (CRC).

Immunotherapy has been an exciting addition to the armamentarium of metastatic CRC in the past few years, explains Morris.

However, only approximately 3% to 5% of all patients with metastatic CRC have microsatellite instability–high disease that is amenable to immunotherapy, says Morris. These patients can have favorable long-term outcomes with immunotherapy.

Translating these outcomes to patients with metastatic CRC who have microsatellite stable disease is an area of active research, concludes Morris.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
V. Craig Jordan, PhD
July 22nd 2024

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 11th 2024

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

Guillermo Garcia-Manero, MD
July 17th 2024

Real-World and Post-Hoc Analyses Support Luspatercept Use in Low-Risk Myelodysplastic Syndrome

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Daniel M. Halperin, MD, of The University of Texas MD Anderson Cancer Center
June 27th 2024

Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETs

Barbara Jane O’Brien, MD, of The University of Texas MD Anderson Cancer Center
June 21st 2024

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis